LeMaitre Vascular, Inc. $LMAT Stake Raised by Annex Advisory Services LLC

Key Points

• Annex Advisory Services LLC increased its stake in LeMaitre Vascular by 535.2% during the second quarter, now owning 219,667 shares valued at approximately $18.2 million.
• Analysts have set new price targets for LeMaitre Vascular, with Barrington Research and Cantor Fitzgerald both raising their target prices to $95.00, indicating a positive outlook for the stock.
• LeMaitre Vascular recently declared a quarterly dividend of $0.20 per share, translating to an annualized yield of 0.9% and a payout ratio of 38.83%.

Annex Advisory Services LLC grew its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 535.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 219,667 shares of the medical instruments supplier's stock after acquiring an additional 185,085 shares during the period. Annex Advisory Services LLC owned about 0.97% of LeMaitre Vascular worth $18,243,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LMAT. Opal Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the first quarter valued at about $26,000. NBC Securities Inc. acquired a new position in LeMaitre Vascular in the first quarter worth about $36,000. Geneos Wealth Management Inc. grew its stake in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 398 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in LeMaitre Vascular in the first quarter worth about $50,000. Finally, US Bancorp DE grew its stake in LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 368 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on LMAT. Barrington Research reiterated an "outperform" rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Tuesday. Cantor Fitzgerald lifted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Stock Performance

NASDAQ LMAT traded down $1.70 during trading hours on Tuesday, reaching $90.59. The company's stock had a trading volume of 81,919 shares, compared to its average volume of 189,765. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The business has a 50-day simple moving average of $90.69 and a 200 day simple moving average of $86.05. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The stock has a market cap of $2.05 billion, a PE ratio of 44.02, a PEG ratio of 2.37 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. During the same quarter last year, the company posted $0.52 earnings per share. LeMaitre Vascular's revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's payout ratio is 38.83%.

Insiders Place Their Bets

In other news, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the sale, the chief executive officer owned 1,727,003 shares of the company's stock, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the sale, the director directly owned 2,916 shares in the company, valued at approximately $274,104. This trade represents a 46.16% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.